Physician profile
Abeera Ali
NPI 1699150409
$2,617.71
in general payments reported to CMS, 2019-2025
32 companies · $589 in 2025
The $589 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $98.05 · 2021: $110 · 2022: $590 · 2023: $503 · 2024: $575 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $906.24 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Ge Healthcare | $176.13 | 2022-2025 | |
| Pfizer INC. | $141.48 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $135.29 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $116.27 | 2019-2025 | Ajovy |
| Ucb, INC. | $115.57 | 2019-2025 | Fintepla |
| Allergan, INC. | $105.00 | 2019-2021 | |
| Lilly USA, LLC | $84.43 | 2019-2024 | Reyvow, Emgality |
| Argenx US, INC. | $83.55 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Livanova USA, INC. | $77.47 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $61.34 | 2019-2024 | Skyclarys |
| Lundbeck LLC | $58.82 | 2023-2025 | Vyepti |
| Eisai INC. | $55.74 | 2022-2025 | |
| Tg Therapeutics, INC. | $53.44 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $53.11 | 2019-2024 | Ongentys 50mg Capsules 30, Crexont |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $47.74 | 2022-2024 | Ingrezza, Ongentys |
| Avion Pharmaceuticals | $45.76 | 2022 | |
| Celgene Corporation | $34.16 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $33.52 | 2025 | Dysport |
| Corium, LLC | $27.73 | 2023 | Adlarity |
| Sk Life Science, INC. | $25.93 | 2022 | |
| Genzyme Corporation | $22.70 | 2021 | |
| Alnylam Pharmaceuticals INC. | $22.54 | 2023 | Onpattro |
| Mallinckrodt Enterprises LLC | $21.90 | 2019 | |
| Genentech USA, INC. | $20.12 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.13 | 2024 | Ultomiris |
| Acadia Pharmaceuticals INC | $14.48 | 2024 | Daybue |
| Averitas Pharma INC. | $14.16 | 2025 | Qutenza |
| Sunovion Pharmaceuticals INC. | $14.01 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.21 | 2021 | |
| Sumitomo Pharma America, INC. | $4.74 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abeera Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.